Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Your child may be eligible for this trial if he/she:~* Had a kidney transplant 1 year ago or more;~* Is between 2 and 21 years of age (parent or guardian's signed informed consent required if under 18);~* Is taking stable, maintenance doses of immunosuppressive drugs for his/her kidney transplant; and~* Is generally in good health.~Exclusion Criteria:~Your child will not be eligible for this trial if he/she:~* Has had any rejection episodes in the last 6 months or has other problems with their kidneys;~* Was in the hospital for a major infection in the last 30 days;~* Has a history of VZV infection, including chicken pox or shingles;~* Has ever received a VZV vaccine, including Varivax®;~* Lives with a person whose immune system does not work well;~* Is allergic to certain medications;~* Is unable to return for the prescribed follow-up check-ups;~* Has no phone or pager; or~* Has had blood or plasma transfusions or taken certain drugs in the last 6 months.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Varivax® (Type: EXPERIMENTAL): 0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).

Based on this trial design, predict the completion outcome and termination type (if applicable).